Dexcom and Nick Jonas Unveil First-Ever Super Bowl Commercial, Calling for Better Care for People With Diabetes
2.2.2021 18:00:00 EET | Business Wire | Press release
DexCom, Inc. (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, debuted today its first-ever Super Bowl commercial, starring multi-platinum recording artist, actor and philanthropist Nick Jonas, who was diagnosed with Type 1 diabetes at the age of 13. The ad, which will run during Super Bowl LV on Feb. 7, 2021, calls for better care for people with diabetes who are still painfully pricking their fingers to measure their glucose levels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210202005348/en/
Nick Jonas wearing the Dexcom G6 Continuous Glucose Monitoring (CGM) system. Photo courtesy of Dexcom. (Photo: Business Wire)
“Too many people with diabetes suffer through painful, antiquated fingerpricks because they don’t know a better way exists,” said Jonas. “I truly believe people with diabetes deserve the absolute best care, and that’s really the spirit of my first Super Bowl commercial. It means so much to me to bring this message of awareness and the need for improved CGM access to as many people with diabetes as possible.”
Tens of millions of people with diabetes around the world are still pricking their fingers, signaling a lack of awareness and the need to improve access for game changing CGM technology that has revolutionized diabetes management.
The Dexcom G6 CGM system uses a small wearable sensor and transmitter to measure and send real-time glucose values wirelessly to a compatible smart device or receiver,* eliminating the need for painful fingerpricks. † Dexcom CGM also displays trend arrows to show the speed and direction glucose levels are heading, making in-the-moment treatment decisions easier and helping people with diabetes avoid potentially dangerous high or low glucose events. ‡
The ad, which will air at the end of the first quarter, shows how much various technologies have advanced over the last 40 years—contrasted by the realization that people with diabetes are still pricking their fingers to measure their glucose, a method invented in the 1970s.
“We are very excited to partner with Nick to shed light on technology that we know can significantly improve the lives of people with diabetes,” said Chad Patterson, senior vice president of global marketing for Dexcom. “People with diabetes deserve the best care, so along with leading diabetes advocacy groups, healthcare professionals and payers we are trying to increase awareness and improve access for CGM.”
As COVID-19 persists, Super Bowl parties are expected to look very different this year. For people with diabetes, a group at higher risk of COVID-19-related complications, social distancing and avoiding large gatherings is especially important. To help people feel less isolated on Super Bowl Sunday, Dexcom is giving fans the opportunity to “watch the game” with Nick Jonas through an interactive augmented reality experience.
Visit DexcomGameDay.com to see the commercial and find out how to watch the Super Bowl with Nick Jonas.
While the Super Bowl offers an enormous stage to launch this important conversation, Dexcom and Nick Jonas will be teaming up with leading diabetes nonprofits in the coming weeks to continue the discussion about better awareness, education and access for diabetes management technology. Organizations involved in this effort will include Beyond Type 1, the nonprofit co-founded by Nick, Children with Diabetes, College Diabetes Network, JDRF International and Taking Control of Your Diabetes.
To learn more about Dexcom CGM, visit Dexcom.com
About DexCom, Inc.
DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. For more information, visit www.dexcom.com.
* For a list of compatible devices, visit www.dexcom.com/compatibility.
† If your glucose alerts and readings from the Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
‡ The urgent low soon can warn you in advance of severe hypoglycemia—allowing you time to take appropriate action before it happens.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005348/en/
Contact information
Media Contact:
James McIntosh, (619) 884-2118
Dexcom Public Relations
james.mcintosh@dexcom.com
Investor Contact:
Steve Pacelli, (858) 200-0200
Dexcom Strategy and Corporate Development
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angelalign Technology Inc. (6699.HK) Applauds European Court Rejection of Patent Infringement Claim12.5.2026 20:39:00 EEST | Press release
Angelalign Technology Inc. (6699.HK) (“Angel”) (http://www.angelaligner.com) today said it was grateful that the Local Division Düsseldorf (Germany) of the Unified Patent Court rejected a request by Align Technology Inc. (ALGN) for Angel to cease and desist from using its A7 Premolar Extraction Solution. Angel denied that the A7 tooth movement protocol infringes any patents as alleged by Align Technology Inc. (ALGN). The court rejected Align’s request for Angel to preliminarily cease its use of the feature, a decision Angel applauded. “We respect the Düsseldorf Local Division’s ruling and will continue to make our case that Angel has not violated any valid patents,” said Dr. Arno Riße, Angel’s attorney at the Arnold Ruess law firm of Düsseldorf. “We are grateful that the court decided not to grant Align's request for preliminary measures. Angel takes intellectual property rights seriously and is careful not to infringe on legitimate patents.” “We categorically deny the allegations of i
Bharat Forge Signs Long-Term Contract with Embraer for Landing Gear Forgings12.5.2026 19:38:00 EEST | Press release
Bharat Forge Ltd. (BFL) (BSE: 500493, NSE: BHARATFORG), a global leader in advanced forging and precision engineering, today announced a long-term contract with Embraer for the manufacturing and supply of critical landing gear forgings. With this milestone, Bharat Forge becomes the first Indian supplier to join Embraer’s global aerospace supply chain for forged components. Under the agreement, Bharat Forge will supply high-integrity forged components for landing gear systems across Embraer’s commercial and Defence aircraft programs. This engagement establishes a strategic partnership anchored in advanced manufacturing capabilities, precision engineering, and proven expertise in delivering complex, safety-critical components for global aerospace platforms. The long-term contract reflects a shared commitment to quality, reliability, and sustained collaboration, and reinforces Embraer’s confidence in Bharat Forge’s ability to meet stringent global certification standards while consistentl
De' Longhi Group - 6.6% Growth at Constant Exchange Rates and Accelerated Net Profit: Solid Results Fully Support Guidance12.5.2026 19:37:00 EEST | Press release
The Board of Directors of De' Longhi S.p.A. approved the consolidated results 1for the first quarter of 2026: In the first quarter the Group achieved: revenues of € 777.7 million, up 3% (+6.6% at constant exchange rates); adjusted 2Ebitda of € 125.9 million, equal to 16.2% of revenues (15.4% in Q1-25); net profit (pertaining to the Group) of € 61.7 million, equal to 7.9% of revenues and up 7.5% compared to the previous year; net financial position at the end of March 2026 of € 720.5 million. CEO Fabio de' Longhi commented: “The start of 2026 was marked by solid revenue growth of 6.6% at constant exchange rates, continuing the excellent performance achieved in recent years. The professional division's strong expansion sustained its momentum, with revenue growing by over 40% and now representing approximately 18% of total quarterly turnover. Simultaneously, we are pleased with the positive organic performance of the household division, which resumed its growth trajectory after successful
Multi-Color Corporation Successfully Completes Comprehensive Financial Restructuring12.5.2026 19:09:00 EEST | Press release
Multi-Color Corporation ("MCC" or the "Company") today announced the successful completion of the Company’s financial restructuring process and emergence from its prepackaged Chapter 11 process. The Company’s prepackaged restructuring reduced net debt by approximately $3.8 billion, reduced annualized cash interest expense by more than $330 million, and extended long-term debt maturities to 2033. More than 99% of voting stakeholders voted to accept MCC’s Plan of Reorganization. Upon emergence, MCC also received a significant $889 million new common and preferred equity investment from CD&R and a group of MCC’s existing secured lenders to support MCC’s long-term growth and investment. "Today marks a significant milestone for MCC, as well as our customers, teammates, and partners who have supported us throughout this process,” said Hassan Rmaile, President and Chief Executive Officer of MCC. “Over the last several months, we continued to diligently serve and win clients, sharpened our ope
New Cessna Caravans to Boost USDA’s Fight Against Crop-Damaging Insects12.5.2026 18:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced that the U.S. Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS) has ordered three Cessna Caravan aircraft to support its sterile insect release program protecting citrus crops along the Rio Grande River in southern Texas. The new aircraft are expected to be delivered in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512676348/en/ Mission-Ready: The Cessna Caravan joins USDA’s fight to protect Texas citrus from invasive pests APHIS will use the Caravans to carry and release sterile insects that help prevent the spread of destructive pests, including fruit flies. The environmentally friendly technique helps safeguard fruit-bearing trees, reduce crop damage and protect agricultural industries that rely on healthy harvests. “These aircraft will help APHIS reach remote areas and carry out their important mission o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
